Literature DB >> 24090597

Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.

Takashi Ishida1, Masakatsu Hishizawa, Koji Kato, Ryuji Tanosaki, Takahiro Fukuda, Yoshifusa Takatsuka, Tetsuya Eto, Yasushi Miyazaki, Michihiro Hidaka, Naokuni Uike, Toshihiro Miyamoto, Mitsuru Tsudo, Hisashi Sakamaki, Yasuo Morishima, Ritsuro Suzuki, Atae Utsunomiya.   

Abstract

Allogeneic hematopoietic cell transplantation (HCT), but not autologous HCT, can provide long-term remission in some patients with adult T cell leukemia-lymphoma (ATL). We retrospectively analyzed the effects of acute graft-versus-host disease (GVHD) among the 616 patients with ATL who survived at least 30 days after allogeneic HCT with other than cord blood grafts. Multivariate analyses treating the occurrence of GVHD as a time-varying covariate demonstrated an association between grade I-II acute GVHD and favorable overall survival (OS) (hazard ratio [HR], 0.634; 95% confidence interval [CI], 0.477 to 0.843), whereas grade III-IV acute GVHD showed a trend toward unfavorable OS (HR, 1.380; 95% CI, 0.988 to 1.927) compared with nonacute GVHD. In subsequent multivariate analyses of patients who survived at least 100 days after HCT (n = 431), the presence of limited chronic GVHD showed a trend toward favorable OS (HR, 0.597; 95% CI, 0.354 to 1.007), and extensive chronic GVHD had a significant effect on OS (HR, 0.585; 95% CI, 0.389 to 0.880). There were no significant interactions between myeloablative conditioning or reduced-intensity conditioning with OS even when acute GVHD was absent or present at grade I-II or grade III-IV or when chronic GVHD was absent, limited, or extensive. This study demonstrates the actual existence of graft-versus-ATL effects in patients with ATL regardless of whether myeloablative conditioning or reduced-intensity conditioning is used.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATL-related mortality; HTLV-1; Mogamulizumab; TRM

Mesh:

Year:  2013        PMID: 24090597     DOI: 10.1016/j.bbmt.2013.09.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  20 in total

1.  Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP.

Authors:  A Bazarbachi; K Cwynarski; A Boumendil; H Finel; P Fields; K Raj; A Nagler; M Mohty; A Sureda; P Dreger; O Hermine
Journal:  Bone Marrow Transplant       Date:  2014-07-14       Impact factor: 5.483

2.  Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study.

Authors:  Makoto Hirosawa; Midori Goto; Masahiko Oku; Kenichi Akao; Noriaki Kitamura; Tsukasa Nakanishi; Aya Tanaka; Daisuke Niino; Takehiro Higashi; Hiroaki Morimoto; Junichi Tsukada
Journal:  Int J Hematol       Date:  2022-09-09       Impact factor: 2.319

3.  Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.

Authors:  Yuma Sakamoto; Takashi Ishida; Ayako Masaki; Takayuki Murase; Morishige Takeshita; Reiji Muto; Hiromi Iwasaki; Asahi Ito; Shigeru Kusumoto; Nobuaki Nakano; Masahito Tokunaga; Kentaro Yonekura; Yukie Tashiro; Shinsuke Iida; Atae Utsunomiya; Ryuzo Ueda; Hiroshi Inagaki
Journal:  Br J Haematol       Date:  2021-08-17       Impact factor: 8.615

Review 4.  Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?

Authors:  E H Phillips; A Hodson; O Hermine; A Bazarbachi; K Cwynarski
Journal:  Bone Marrow Transplant       Date:  2016-09-12       Impact factor: 5.483

Review 5.  Modes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and Persistence.

Authors:  Alexandre Carpentier; Pierre-Yves Barez; Malik Hamaidia; Hélène Gazon; Alix de Brogniez; Srikanth Perike; Nicolas Gillet; Luc Willems
Journal:  Viruses       Date:  2015-07-07       Impact factor: 5.048

6.  Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil.

Authors:  Pedro Dantas Oliveira; Ítala Gomes; Victor Hugo Gomes Souza; Ernesto Cunha Pires; Glória Bomfim Arruda; Achiléa Bittencourt
Journal:  Rev Bras Hematol Hemoter       Date:  2016-10-22

7.  Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.

Authors:  Takashi Ishida; Atae Utsunomiya; Tatsuro Jo; Kazuhito Yamamoto; Koji Kato; Shinichiro Yoshida; Shigeki Takemoto; Hitoshi Suzushima; Yukio Kobayashi; Yoshitaka Imaizumi; Kenichi Yoshimura; Kouichi Kawamura; Takeshi Takahashi; Kensei Tobinai; Ryuzo Ueda
Journal:  Cancer Sci       Date:  2017-08-28       Impact factor: 6.716

8.  GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.

Authors:  Hiroyuki Muranushi; Takero Shindo; Masakatsu Hishizawa; Masahito Tokunaga; Atsushi Wake; Nobuaki Nakano; Tetsuya Eto; Michihiro Hidaka; Ilseung Choi; Toshihiro Miyamoto; Naoyuki Uchida; Yukiyoshi Moriuchi; Yasuhiko Miyazaki; Takahiro Fukuda; Tatsuo Ichinohe; Yoshiko Atsuta; Koji Kato
Journal:  Bone Marrow Transplant       Date:  2020-07-14       Impact factor: 5.483

9.  Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.

Authors:  Yukie Tsubokura; Atsushi Satake; Masaaki Hotta; Hideaki Yoshimura; Shinya Fujita; Yoshiko Azuma; Takahisa Nakanishi; Aya Nakaya; Tomoki Ito; Kazuyoshi Ishii; Shosaku Nomura
Journal:  Int J Hematol       Date:  2016-08-29       Impact factor: 2.319

Review 10.  Optimizing Management of Patients with Adult T Cell Leukemia-Lymphoma.

Authors:  Jean A Yared; Amy S Kimball
Journal:  Cancers (Basel)       Date:  2015-11-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.